Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818742 | 0.87 | SMO (0.58) | MAPTMEN1KMT2AGAANPSR1 | |
| SCHEMBL2819678 | 0.86 | MAPT (0.62) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2822758 | 0.83 | KMT2A (0.63) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2818641 | 0.82 | TSHR (0.65) | MAPTMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL13254748 | 0.82 | KCNK3 (0.60) | MAPTMEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL2822415 | 0.82 | ADORA3 (0.61) | MAPTMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL2820197 | 0.81 | ADORA3 (0.69) | MAPTMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL4198997 | 0.81 | BRAF (0.72) | XDHSLC22A12BRAFFYNADORA3 | |
| SCHEMBL2820201 | 0.80 | XDH (0.47) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL1499710 | 0.80 | MAPT (0.70) | MAPTMEN1KMT2AMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288421-B2 | neoplastic disease, autoimmune disease, transplantation related pathology and/or degenerative disease; selectively inducing apoptosis in cancer cells | BASILEA PHARMACEUTICA AG (CH) | 2012-10-16 | — | — | US | claimed |
| EP-1789044-B1 | PHENYLAMINOPYRIDINES AND PHENYLAMINOPYRAZINES | BASILEA PHARMACEUTICA AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20080221171-A1 | Phenylaminopyridines | BASILEA PHARMACEUTICA AG (CH) | 2008-09-11 | — | — | US | claimed |
| EP-1789044-A1 | PHENYLAMINOPYRIDINES | Basilea Pharmaceutica AG (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006027348-A1 | PHENYLAMINOPYRIDINES | BASILEA PHARMACEUTICA AG (CH) | 2006-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221171-A1 | Phenylaminopyridines | P2RY11, BCL9, TPMT | MAPT 4559/4885MEN1 2236/4885KMT2A 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.